world pharmaceutical frontiers providing a global perspective on the industry www worldpharmaceuticals net page i n d u s t r y f g e in figures or many manufacturers 2005 was year of transition as they focused responding to cost containment challenges regulatory setbacks and relatively poor growth from new recently launched products result rise sales at ex manufacturer prices modest 7 per cent lowest recorded since beginning decade almost three percentage points below 9 8 cagr for period 2000 05 see figure 1 future performance will be fuelled by swelling underlying demand driven ageing populations successful innovation areas high unmet need generics continue move centre stage patients bear higher proportion their healthcare costs while payers increase efforts restrict further expenditures balance is expected stabilise 5 range emerging markets blossom slowdown overall saw rebalancing with
